GlassScriptPhysician profile
Alexa Grace Augustine
NPI 1831903780
$2,636.77
in general payments reported to CMS, 2019-2025
21 companies · $2,637 in 2025
The $2,637 reported for 2025 was more than what 97% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186 · Consulting Fee: $400 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.14 |
| Consulting Fee | $400.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $576.81 | 2025 | |
| Janssen Biotech, INC. | $538.45 | 2025 | Carvykti, Rybrevant, Erleada |
| Teleflex LLC | $190.83 | 2025 | Barrigel, Solesta |
| Antares Pharma, INC. | $183.97 | 2025 | Xyosted |
| Sumitomo Pharma America, INC. | $149.58 | 2025 | Gemtesa |
| Ferring Pharmaceuticals INC. | $146.04 | 2025 | Adstiladrin |
| Astellas Pharma US INC | $138.85 | 2025 | Padcev, Veozah |
| Pfizer INC. | $137.98 | 2025 | |
| Blue Earth Diagnostics | $110.47 | 2025 | Posluma |
| Progenics Pharmaceuticals, INC. | $82.86 | 2025 | |
| Endo USA, INC. | $64.21 | 2025 | Xiaflex, Aveed |
| Accord Healthcare, INC. | $60.55 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $51.48 | 2025 | |
| Urogen Pharma, INC. | $41.59 | 2025 | |
| Coloplast Corp | $41.45 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $24.89 | 2025 | Tlando |
| Boston Scientific Corporation | $22.36 | 2025 | Ams 700 |
| Olympus America INC. | $20.26 | 2025 | Itind System |
| Tolmar, INC. | $19.79 | 2025 | Eligard, Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $18.39 | 2025 | |
| Azurity Pharmaceuticals, INC. | $15.96 | 2025 | Azmiro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexa Augustine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.